Advances and challenges in chimeric antigen receptor‐natural killer cell immunotherapy for cancer

Hind Rafei,Katayoun Rezvani
DOI: https://doi.org/10.1111/bjh.19939
2024-12-03
British Journal of Haematology
Abstract:CAR‐NK cell therapy is an emerging immunotherapy for cancer. Recent advancements in genetic engineering have improved their antitumour efficacy through strategies such as dual‐targeting CARs, cytokine armouring and logic gating to minimize fratricide and off‐target effects. Gene‐editing approaches, including checkpoint deletion and overexpression of key effector molecules, further enhance their persistence and cytotoxicity. Additionally, the availability of diverse NK cell sources, such as peripheral blood, umbilical cord blood, CD34+ haematopoietic stem and progenitor cells, and iPSCs, offers scalability and flexibility for clinical applications. These innovations position CAR‐NK cells as a versatile and potent therapeutic platform for treatment‐resistant malignancies. Chimeric antigen receptor (CAR)‐natural killer (NK)‐cell therapy has emerged as a promising strategy in the treatment of haematological malignancies and solid cancers. Leveraging the innate immune properties of NK cells, CAR‐NK‐cell therapies offer potential advantages for cell therapy, including safety of use in the allogeneic setting and reduced risk of toxicity. This Nutshell provides an overview of the latest advancements in CAR‐NK‐cell therapy and the challenges that remain.
hematology
What problem does this paper attempt to address?